INTRODUCTION
============

The voltage-gated sodium channels determine the rising phase of an action potential and the length of the refractory period in nerves, skeletal muscle, and heart ([@bib6]; [@bib13]). Local anesthetics along with antiarrhythmics and anticonvulsants comprise a group of compounds that are clinically one of the most important and widely used modifiers of sodium channel function ([@bib8]). When used to treat peripheral pain, they simply block the pore of the sodium channels in resting state, thereby preventing further propagation of action potentials. On the other hand, the primary mode of action of anticonvulsants and antiarrhythmics is to block the sodium currents in a frequency-dependent manner ([@bib35]). This phenomenon, termed as use-dependent block, makes the drug a more potent blocker when the sodium channels activate with a higher frequency. Thus, these "smart" compounds behave as low frequency filters in an electrical circuit, attenuating uncontrolled high frequency activity associated with disease states such as arrhythmias and epilepsies.

To account for these striking effects of local anesthetics on the sodium channel, it has been proposed that these drugs bind with a high affinity to the open/inactivated state relative to the closed state of the channel ([@bib12]). Alternatively, the guarded receptor hypothesis postulates that the binding site for the local anesthetic is gated and becomes accessible only when the channel opens ([@bib35]; [@bib34]). Although both of these models can rationalize the basic phenomenology, several lines of evidence suggest that the presence of a local anesthetic profoundly modifies the voltage-dependent gating behavior of the sodium channel. Gating current measurements show that the total charge associated with channel activation is reduced in the presence of local anesthetics ([@bib15]; [@bib23]; [@bib4]; [@bib5]; [@bib36]; [@bib10]; [@bib29]). Fluorescence--voltage (F-V) curves of probes attached to domain III voltage sensor were shifted to more hyperpolarized potentials upon the addition of lidocaine ([@bib21]). Moreover, this modification of the voltage sensor is tightly linked to use-dependent block of sodium currents ([@bib11]; [@bib21]). These findings suggest that the voltage sensor of domain III is stabilized in the activated state upon use-dependent block of sodium currents by local anesthetics. Structure--function studies implicate a cluster of residues in the S6 helices lining the central pore as the binding site primarily responsible for use-dependent block ([@bib25]; [@bib40]; [@bib43]; [@bib41]; [@bib45], [@bib46]). Because the voltage-sensing domain is likely to be a well-defined structural module separate from the pore domain ([@bib18], [@bib19]), these findings suggest that local anesthetic binding to the pore allosterically modulates the voltage sensors of the sodium channel. Similar studies in the inactivation-removed Shaker potassium channel show that the OFF gating current is reduced in the presence of tetra-ethylammonium ions ([@bib3]). Thus, allosteric modification of voltage gating by pore blockers may be a common feature of the voltage-dependent ion channel superfamily.

To determine molecular pathway--mediating interaction between the lidocaine-binding site and domain III voltage sensor of the sodium channel, we focused on the role of the intracellular gating interface. Studies in the Shaker potassium channel have identified two gating interfaces that are likely to be involved in electromechanical coupling of the voltage sensor and pore gates ([@bib28]; [@bib31],[@bib32]; [@bib16]; [@bib9]; [@bib20]; [@bib33]; [@bib17]). Mutagenesis and domain swap experiments have shown that residues in the S4--S5 linker and the intracellular end of S5 and S6 play a crucial role in coupling S6 segments to the voltage sensor movement. [@bib17] have suggested that the interface between S1 and the neighboring S5 segment is also involved in electromechanical coupling. In this study, we systematically mutated residues in the S4--S5 linker and S5 and S6 segments in domain III and examined the effect of lidocaine on the movement of this voltage sensor using voltage clamp fluorimetry and gating current measurements. The binding of lidocaine to the wild-type (WT) skeletal muscle sodium channel shifts the midpoints of the activation curves of domain III voltage sensor by \>50 mV in the hyperpolarizing direction. We identify a set of residues that when mutated to a tryptophan dramatically reduce the effect of lidocaine on the steady-state properties of domain III voltage sensor. Measurements of gating currents show that lidocaine block of sodium currents in these mutants has a much smaller effect on the total gating charge modification compared with the WT sodium channels. Moreover, the maximal use-dependent block of the mutants is comparable to the WT channels. These findings suggest that the intracellular gating interface is a major pathway for allosteric modulation of voltage sensor movement by local anesthetics.

MATERIALS AND METHODS
=====================

Molecular biology and oocyte expression
---------------------------------------

All mutants were generated in the background of the mutant (L1115C) rat skeletal muscle sodium channel (rNav 1.4), as described previously ([@bib22]). cDNAs of both α and β subunit of rNav 1.4 were linearized with NotI digestion (New England Biolabs, Inc.) and transcribed using the mMESSAGE mMACHINE T7 kit (Applied Biosystems). Equimolar ratios of α and β subunit mRNAs were coinjected into *Xenopus laevis* oocytes to a final volume of 50 nL. Oocytes were obtained from Nasco or surgically removed from *Xenopus* according to the guidelines of the Animal Care and Use Committee at the University of Wisconsin-Madison. After injection, the oocytes were kept at 18°C in a solution containing (in mM): 100 NaCl, 2 KCl, 1.8 CaCl~2~, 1 MgCl~2~, 5 HEPES, 0.1 DTT, and 0.2 EDTA, supplemented with 100 µg/ml gentamicin and 100 mg/ml bovine serum albumin. Measurements were performed within 1--7 d after injection.

Fluorescence and electrophysiology measurements
-----------------------------------------------

The oocytes were incubated for labeling with 10 µM tetramethyrhodamine maleimide (TMRM; Invitrogen) in a depolarizing solution (in mM: 110 KCl, 1.5 MgCl~2~, 0.8 CaCl~2~, and 10 HEPES, pH 7.5) on ice for 30 min. 10 mM TMRM stock solution was prepared in DMSO and stored at −20°C. Labeled oocytes were washed and stored at room temperature in 115 mM *N*-methyl glucamine (NMG) containing external solution until recording. All recordings were obtained at room temperature (22 ± 3°C). Fluorescence recordings were performed as described previously ([@bib21]). In brief, the labeled oocytes were positioned in a modified cut-open oocyte setup (CA-1B; Dagan Corporation) and placed on a stage of an upright microscope (BX50WI; Olympus), and the current and fluorescence signals were simultaneously measured under voltage clamp conditions. The light from a xenon lamp source (Hamamatsu Photonics) was filtered with a 535/HQ50 bandpass filter and split using a Q565LP dichroic mirror (Chroma Technology Corp.). The emitted light was filtered with a 610/HQ75 bandpass filter and focused onto a PIN-020A photodiode (UDT Instruments) by a condenser lens. The photodiode was connected to the integrating headstage of a patch clamp amplifier (Axopatch 1B; Axon Instruments, Inc.). Gating current recordings were obtained using the cut-open oocyte technique. 10 µM tetrodotoxin (TTX) was first added to the external solution in the top and middle chambers, followed by lidocaine application. Measurements of use-dependent block were obtained using the two-electrode voltage clamp setup (OC-725C Oocyte Clamp; Warner Instruments).

Recording solutions
-------------------

Fluorescence and gating current recordings obtained in the presence of external solution (105 mM NMG-Mes, 20 mM HEPES, and 2 mM Ca^2+^, pH 7.4) and internal solution (105 mM NMG-Mes, 20 mM HEPES, and 2 mM EGTA, pH 7.4) were used. Ionic current recordings were obtained in two-electrode voltage clamp setup, with an external solution composed of 21 mM NaMes, 84 mM NMG-Mes, 20 mM HEPES, and 2 mM Ca^2+^, adjusted to pH 7.4.

Data acquisition and analysis
-----------------------------

Analogue signals were sampled at 250 kHz with a Digidata 1440 interface (MDS Analytical Technologies) and low-pass filtered at 10 kHz. For gating current measurements, linear leak and membrane capacitive current were subtracted online by a P/4 procedure with a subtraction holding potential of +50 mV. Gating currents were obtained by applying a 20-ms test pulse to voltages ranging from −130 to +40 mV, with a pre- and post-pulse of 50 ms at −130 mV. The holding potential was −80 mV.

Each fluorescence trace represents an average of 10 recordings obtained by a 20-ms test pulse from −120 mV after a 20-ms conditioning pulse at −10 mV, with a holding potential of −80 mV. The interval between the conditioning and test pulse was 100 ms. The conditioning pulse was used to ensure that the channel was fully blocked by lidocaine. Fluorescence intensity decay from photobleaching was corrected by fitting the trace to a single exponential or a straight line and subtracting it from the original trace. The data were subsequently low-pass filtered offline at 5 kHz.

F-V and gating charge--voltage (Q-V) curves were fitted to a single Boltzmann function:$$\frac{F}{F_{\text{max}}}\left( V \right)or\frac{Q}{Q_{\text{max}}}\left( V \right) = \frac{1}{1 + \text{exp}^{\frac{( - \mathit{ze}(V - V_{1/2}))}{\mathit{KT}}}},$$where z is the apparent valence, e is the electronic charge, V~1/2~ is the half-maximal voltage, K is the Boltzmann constant, and T is the temperature.

To measure use-dependent block, 100 test pulses of 20 ms at −20 mV (10 Hz) from a holding potential of −80 mV were applied. The pulsing frequency was varied to measure frequency-dependent block. All data were acquired using Clampex (MDS Analytical Technologies) and analyzed with Clampfit, Excel (Microsoft), or Origin (GE Healthcare). Prism (GraphPad Software) was used for statistical analysis.

Homology modeling
-----------------

The homology models of the sodium channel in the open state were developed using the crystal structure of the K~V~1.2/2.1 chimera (Protein Data Bank accession no. [2R9R](2R9R)) as a template. The sequences of the putative sodium channel domains were first aligned to the template sequences using ClustalW ([@bib37]), with default alignment parameters. The alignment was manually optimized to minimize the gaps within the putative transmembrane segments of the different sequences ([Fig. S1](http://www.jgp.org/cgi/content/full/jgp.201010438/DC1)). The homology modeling was performed using Modeller 9v4 ([@bib26]). 100 candidate models (S1 through S6) were generated for each of the four domains of the sodium channel. The final model for each domain was selected on the basis of the DOPE (discrete optimized potential energy) scores and the stereochemical quality of the candidate models, as assessed from the Ramachandran plots. The models of the four domains were organized symmetrically around the axis of K^+^ conduction by using an appropriate transformation of coordinates to generate the final tetrameric structure. To remove certain bad contacts/steric clashes, especially in the membrane reentrant loop (pore helix) between S5 and S6, it was necessary to move each of the four domains radially outward (by 1.5 Å). In vacuo energy minimization of this tetrameric structure was performed using NAMD 2.6 ([@bib24]), with the CHARMM 27 force field parameters and with all atomic charges switched off.

Modeling state occupancies
--------------------------

The expressions for the probability of the voltage sensor activation in the absence and presence of lidocaine, as derived from Scheme 2 ([Eqs. 1](#fd1){ref-type="disp-formula"} and [2](#fd2){ref-type="disp-formula"}), were fitted to the corresponding F-V data. The data fitting of both equations was performed simultaneously, so that one dataset served as a constraint for the other. Fitting was performed using the MATLAB curve-fitting toolbox (robust nonlinear least-squares method, Levenberg-Marquardt algorithm) to obtain the values of the different thermodynamic parameters. The parameters K~V~, K~P~, and K~R~ are all voltage-dependent equilibrium constants, and their voltage dependence can be expressed as $\left. K_{i} = K_{i}^{0}\text{exp}\operatorname{\,(}z_{i}\mathit{FV}\beta \right),$ where *i* = V, P, or R. The voltage dependence of activation of the voltage sensor (with unbound lidocaine), z~V~, is related to that of the deactivation (or return) of the voltage sensor (with bound lidocaine), z~R~, as: z~R~ = −z~V~. The binding affinity (or association constant) of lidocaine, K~A~ (which is the product of the equilibrium binding constant and the concentration of lidocaine), and the coupling parameter θ are considered to be voltage independent.

For the first run of the fitting, the initial guesses of the different parameters were taken from our previous study ([@bib22]), and a set of optimized parameters was obtained. The robustness of the fit was checked by repeating the fitting procedure 1,000 times. For every iteration, six random numbers between 10^−2^ and 10^2^ were generated. Each of the six parameters, obtained from the first run, was scaled separately by the random numbers. The rescaled parameter values were used as the initial estimates to repeat the fitting procedure. Thus, this random sampling algorithm allows us to efficiently search a six-dimensional parameter space spanning over four orders of magnitude and generate a probability distribution of the optimized value for each parameter. The mean and the percent standard deviation for the optimized parameters are reported in [Table II](#tbl2){ref-type="table"}. This fitting procedure was performed on the WT data and on one of the high impact mutants (A1145W). The simulated F-V traces are shown in [Fig. 6](#fig6){ref-type="fig"}.

Online supplemental material
----------------------------

Fig. S1 shows a sequence alignment of the four domains of the rNav 1.4 channel with Kv1.2/2.1 chimera and KcsA channel. Thermodynamic relationships between obligatory and nonobligatory coupling models are described in the supplemental text. Parameters obtained by fitting F-V curves to a Boltzmann function are shown in Table S1. The supplemental material is available at <http://www.jgp.org/cgi/content/full/jgp.201010438/DC1>.

RESULTS
=======

Mutations in the cytoplasmic gating interface alter the drug-induced shift in voltage sensor movement
-----------------------------------------------------------------------------------------------------

The tryptophan-scanning mutagenesis was performed in the intracellular gating interface of domain III of the sodium channel ([Fig. 1](#fig1){ref-type="fig"}). This interface was formed in part by the S4--S5 linker region and the intracellular ends of the S5 and S6 transmembrane segments. The effect of these mutations on allosteric coupling was assessed by attaching a fluorophore, tetramethylrhodamine, near the extracellular end of the S4 segment of domain III and monitoring the changes in fluorescence intensity in response to lidocaine block of ionic currents. Previous studies have shown that the voltage-dependent fluorescence intensity changes from a probe on Leu1115 position in the muscle sodium channel correlate with its gating charge movement and are likely to be reporters of voltage-dependent conformational changes associated with the S4 of domain III movement ([@bib7]).

![Sequence alignment of the putative transmembrane segments of domain III of the brain, nerve, and the muscle sodium channels (Nav1.2, Nav1.4, and Nav1.5) with a chimeric potassium channel (Kv1.2/2.1). The conserved positive charges of the S4 transmembrane segment are highlighted in green. The mutated regions in the S4--S5 linker, N terminus of S5, and C terminus of S6 are shown in red. The fluorophore was attached to an introduced cysteine at the L1115C (in orange) position.](JGP_201010438_RGB_Fig1){#fig1}

55 mutants were generated in the background of the L1115C mutant sodium channel. This L1115C mutant is hereafter referred to as the WT channel. Most mutations were tryptophan substitutions, which because of their large side chain volume are likely to disrupt the tight packing at the interfaces. When, in some instances, tryptophan substitutions resulted in nonfunctional protein or low expression, alanine was substituted. The effect of these mutations on the conductance--voltage relationships and voltage-dependent fluorescence of domain III has been characterized in a recent study ([@bib22]). [Fig. 2 A](#fig2){ref-type="fig"} shows a comparison of representative voltage-dependent fluorescence traces before and after the addition of lidocaine in the WT and two mutants (A1145W and I1287W). Normalized F-V relationships were obtained by plotting the fluorescence intensities near the end of a 20-ms depolarizing pulse with respect to the membrane potential. 10 mM lidocaine in the bath ensures complete block of WT and mutant channels. To quantitatively assess the effect of these mutations, the data were fitted to a single Boltzmann function, and the values of the two parameters, the slope (z), and the voltage-eliciting half-maximal response (V~1/2~) were obtained. In the WT channel, the addition of lidocaine causes a dramatic shift in the F-V curve, such that the V~1/2~ is shifted to a more hyperpolarized potential by −56.1 mV ([Fig. 2 B](#fig2){ref-type="fig"}, left). [Fig. 2 B](#fig2){ref-type="fig"} (middle and right) shows two representative tryptophan mutants, A1145W and I1287W, where the drug-induced shifts of F-V curves by lidocaine were reduced. The effect of lidocaine on the F-V curves for all the mutants is summarized in [Fig. 2 C](#fig2){ref-type="fig"} and [Table S1](http://www.jgp.org/cgi/content/full/jgp.201010438/DC1). Approximately half of the mutants show significantly reduced F-V shifts, and a majority of those are in the S4--S5 linker and S6 segment of domain III. The mutants that produce a \<20-mV hyperpolarizing shift in V~1/2~ in the presence of lidocaine were designated as high impact mutants, whereas those that produce shifts \>20 mV but \<55 mV were designated as low impact mutants. [Fig. 2 C](#fig2){ref-type="fig"} shows that only seven (R1135W, V1142W, A1145W, S1276W, I1284W, I1287W, and K1295W) out of the 55 tested in this study show a \<20-mV hyperpolarizing shift in the V~1/2~ in the presence of lidocaine. Mutations in 17 other sites were designated as low impact mutants.

![Effect of lidocaine on the energetics of the domain III voltage sensor. (A) Time course of voltage-dependent fluorescence signals from domain III of WT and a couple of representative mutant sodium channels. Fluorescence traces were obtained before and after 10-mM lidocaine application by pulsing to a test potential (ranging from +50 to −210 mV) for 20 ms, with a prepulse to −120 mV for 20 ms. Each trace represents an average of 10 trials with an interval of 1 s between each pulse. The scale bars are provided as insets, and the percentage fluorescence changes (ΔF/F) are on the y axis. (B) Steady-state F-V curves before (filled symbols) and after (open symbols) 10-mM lidocaine application. The lines represent the best fits of the averaged data to a single Boltzmann function. The error bars represent the average ± SEM for each data point. (C) Summary of shifts in F-V curves of WT and various mutants upon the application of lidocaine. ΔV~1/2~ was obtained as: ΔV~1/2~ = V~1/2(after\ lidocaine)~ − V~1/2(before\ lidocaine)~. Each bar represents mean ± SEM of at least three independent oocyte measurements. The gray dashed line represents the shift in F-V curves of WT. To test whether these differences were statistically significant, a one-way ANOVA test was used, followed by a post-hoc Dunnett's test. \*, P \< 0.001; \#, P \< 0.05.](JGP_201010438_GS_Fig2){#fig2}

Mutations in the gating interface alleviate gating charge modification by lidocaine
-----------------------------------------------------------------------------------

Gating charge studies show that local anesthetic block of sodium currents is accompanied by a 21% reduction in the total gating charge ([@bib10]; [@bib30]; [@bib21]) ([Fig. 3 A](#fig3){ref-type="fig"}). If a tryptophan mutation disrupts the interaction between local anesthetic-binding site and domain III voltage sensor, we would predict that the extent of charge modification by lidocaine will be diminished. This hypothesis was tested by measuring charge modification by lidocaine in six of the seven high impact mutants identified by fluorescence measurements. Use-dependent block in S1276W mutant was found to be highly impaired (data shown in the next section); therefore, gating currents for this mutant were not assessed. The Q-V relationships of six high impact mutants before and after the addition of 10 mM lidocaine are shown in [Fig. 3 B](#fig3){ref-type="fig"}. The effect of lidocaine on total gating charge in the mutant channels as compared with WT is summarized in [Fig. 3 C](#fig3){ref-type="fig"}, and the parameters for Boltzmann fits of the Q-V curves are in [Table I](#tbl1){ref-type="table"}. In the WT skeletal muscle sodium channel, lidocaine does not significantly alter the midpoints and the slope of the Q-V relationships, but reduces the maximum gating charge moved in response to large depolarization. The introduction of a tryptophan in the six high impact sites significantly reduces this gating charge modification by lidocaine. In the case of two of the mutants, A1145W and I1284W, the addition of lidocaine has almost no effect on gating charge movement. These findings indicate that mutations in key positions corresponding to the high impact sites in the cytoplasmic gating interface disrupt the interaction between the voltage sensor and the lidocaine-binding site.

###### 

Effect of 10 mM lidocaine on the gating current properties of WT and mutant channels

  Channel         Control (TTX)   Lidocaine (+TTX)   Remaining gating charge                 
  --------- ----- --------------- ------------------ ------------------------- ------------- -------------
            *n*   V~1/2~          z                  V~1/2~                    z             \%
  WT        6     −63.8 ± 2.4     1.34 ± 0.02        −63.3 ± 1.9               1.45 ± 0.03   79.0 ± 3.8
  R1135W    4     −65.9 ± 1.9     1.38 ± 0.06        −63.8 ± 0.8               1.38 ± 0.06   91.4 ± 3.7
  V1142W    4     −50.4 ± 2.9     1.01 ± 0.06        −57.6 ± 0.9               1.19 ± 0.03   90.0 ± 2.5
  A1145W    3     −56.0 ± 2.3     1.00 ± 0.03        −54.3 ± 4.3               1.11 ± 0.03   96.2 ± 1.7
  I1284W    3     −57.3 ± 2.8     1.30 ± 0.11        −54.2 ± 5.7               1.20 ± 0.00   100.0 ± 2.2
  I1287W    3     −55.0 ± 1.2     1.13 ± 0.03        −59.2 ± 1.5               1.33 ± 0.01   92.0 ± 3.6
  K1295W    4     −53.7 ± 3.3     0.93 ± 0.01        −59.2 ± 5.1               1.08 ± 0.02   91.2 ± 2.4

Boltzmann parameters from a first-order fit of the Q-V relationships. All measurements were done in the presence of TTX. Data represent the mean ± SEM of at least three independent experiments (*n*).

![Effect of lidocaine on gating currents of WT and mutant sodium channels. (A; left) Representative ON gating currents of the WT channels and their integrals before and after 10-mM lidocaine application. (Right) Steady-state Q-V relationships of the WT channel before (filled symbols) and after (open symbols) lidocaine application. The gray dashed line represents the average reduction in the total gating charge after lidocaine application. The data represent mean ± SEM of at least three independent measurements. The line represents the best fit of the averaged data to a single Boltzmann function. (B) Steady-state Q-V relationships of mutant channels before (filled symbols) and after (open symbols) 10-mM lidocaine application. The gray dashed line represents the average reduction in the total gating charge after the application of lidocaine to the WT channel. The data represent mean ± SEM of at least three independent measurements, and the smooth lines represent the best fits of the averaged data to a single Boltzmann function. (C) Percentage reduction in the total gating charge upon the application of lidocaine in the WT and mutant channels. The total charge movement was measured by a pulse to +40 mV from −130 mV. The data represent mean ± SEM of at least three independent measurements.](JGP_201010438_GS_Fig3){#fig3}

Effect of mutations on use-dependent block by lidocaine
-------------------------------------------------------

Previous studies have shown that the ability of lidocaine to block sodium currents in a use-dependent manner was essential for modification of the voltage sensor movement ([@bib11]; [@bib21]). Here, we test whether lidocaine at saturating concentrations can inhibit the mutant sodium currents in a use-dependent manner. [Fig. 4 A](#fig4){ref-type="fig"} shows a family of WT sodium current traces elicited by applying 100 depolarizing pulses to −20 mV from a holding potential of −80 mV (10-Hz frequency) in the presence of lidocaine. To obtain a dose--response curve for use-dependent block, the peak sodium current at the 100th pulse is plotted with respect to lidocaine concentration ([Fig. 4 B](#fig4){ref-type="fig"}). The estimated IC~50~ for the L1115C mutant skeletal muscle sodium channel is 20 µM, a value similar to the WT sodium channel ([@bib42]). Use-dependent block for both high and low impact mutants was obtained in the presence of 1 mM lidocaine because the fluorescence and gating charge measurements were recorded under saturating conditions of lidocaine ([Fig. 4 C](#fig4){ref-type="fig"}). At this concentration of lidocaine, ∼70% of the WT sodium channels are blocked in a use-dependent manner. Most mutants exhibit similar use-dependent block, which suggests that the loss of voltage sensor modification is not because of their inability to bind to lidocaine. Only 4 out of the 25 show a significantly lower use-dependent block at these drug concentrations. The most dramatic effect was observed upon mutation of the Ser at position 1276, resulting in a significantly diminished use-dependent block of sodium currents. This mutant also exhibits a much smaller shift of F-V curve upon lidocaine addition (ΔV~1/2~ = 20 mV) relative to the WT channels. These findings are consistent with other studies showing that the Serine1276 in the skeletal muscle sodium channel is critical for use-dependent block ([@bib41]).

![Use-dependent block of WT and mutant channels by lidocaine. (A) Representative ionic current traces of WT channel in the presence of different concentrations of lidocaine. Each trace was obtained by applying 100 pulses from −80 to −20 mV for 20 ms at 10 Hz from a holding potential of −80 mV. (B) Dose--response curve for use-dependent block of WT channel by lidocaine. The symbols represent mean ± SEM of at least three independent measurements, and the smooth line represents the best fit of the averaged data to the Hill equation. (C) Percent block of WT and mutant channels after 100 pulses in presence of 1 mM lidocaine. Gray dashed line represents the mean percent block of the WT channel (71.5 ± 2.2%; *n* = 5). The current protocol is the same as in A. In both B and C, the data represent mean ± SEM of at least three independent measurements.](JGP_201010438_GS_Fig4){#fig4}

Next, we examine the correlation between lidocaine-induced shifts of F-V curves and maximal use-dependent block ([Fig. 5](#fig5){ref-type="fig"}). For mutants A1149W and S1276W, use-dependent block at 1 mM lidocaine concentration is much smaller than that of the WT. Furthermore, fluorescence shift induced by lidocaine is also reduced compared to WT. A simple interpretation is that mutations at these positions alter use-dependent block, such that a smaller fraction of the channels compared to the WT is modified. The ionic currents of the other six high impact mutants, in contrast, were blocked in a use-dependent manner, like the WT channels as shown in [Fig. 5](#fig5){ref-type="fig"} (filled circles). Thus, in these mutants the lidocaine block of the sodium currents appears to be largely decoupled from domain III voltage sensor modification. The majority of the low impact mutants show relatively intact use-dependent block but varying degree of lidocaine-induced shifts in F-V curves, suggesting that voltage sensor modification in these mutants is at least partially decoupled from lidocaine binding.

![Relationship between the ΔV~1/2~ of F-V curves and maximal use-dependent block by lidocaine. ΔV~1/2~ of F-V curves upon lidocaine addition and the maximal use-dependent block of ionic currents by lidocaine were obtained as described in the Results. The mutants whose ΔV~1/2~ shifts linearly correlate with use-dependent block are represented as open squares. The mutants that show the most reduction in ΔV~1/2~ without much change in use-dependent block are represented by filled circles, and the remaining mutants that show intermediate levels of reduction in the ΔV~1/2~ are represented by open symbols.](JGP_201010438_LW_Fig5){#fig5}

DISCUSSION
==========

Many intracellular pore blockers allosterically modify the movement of the voltage-sensing charges in voltage-dependent ion channels. High resolution structural and functional studies of K^+^ and Na^+^ channels support the emerging view that S4 motions are transmitted through a gating interface encompassing the S4--S5 linker and the cytoplasmic ends of S5 and S6 helices ([@bib20]; [@bib18]; [@bib33]; [@bib17]; [@bib22]). The motivation for the present study is to investigate the role of this gating interface in coupling the conformation of the lidocaine-binding site to the movement of the voltage sensor in a sodium channel.

Although the notion that lidocaine binding to the sodium channel stabilizes the activated voltage sensor is relatively well established ([@bib29], [@bib30]; [@bib21]), its effect on the pore structure remains controversial. It has been suggested by several groups that lidocaine stabilizes the channel in the inactivated state ([@bib27]). The affinity of the lidocaine to the inactivated cardiac sodium channel was estimated to be 10 µM, comparable to its therapeutic working concentration ([@bib2]). The removal of inactivation in the squid sodium channels by pronase abolished use-dependent block by QX-314, suggesting that the local anesthetics bind mainly to the inactivated channels ([@bib4]; [@bib47]). In contrast to these findings, [@bib39] reported that QX-314 retains its potency on inactivation-deficient sodium currents obtained by treatment with chloramine-T. Cysteine accessibility studies show that the use-dependent block does not involve accumulation of the fast inactivated channels ([@bib38]). Moreover, in another inactivation-deficient mutant sodium channel, the IC~50~ for lidocaine block was found to be comparable to those of the WT channels ([@bib42]). Collectively, these findings suggest that the lidocaine may modulate the transitions that are associated with channel opening, rather than those leading to inactivated states.

Thermodynamic implications of mutations that disrupt allosteric modification
----------------------------------------------------------------------------

Next, we consider a simple qualitative model of an ion channel consisting of a voltage sensor and a pore, each of which can exist in two possible states ([Scheme 1a](#sc1a){ref-type="disp-formula"}). This system exists in four possible states: V~R~P~C~ (pore closed and voltage sensor resting), V~R~P~O~ (voltage sensor resting and pore open), V~A~P~C~ (activated voltage sensor and closed pore), and V~A~P~O~ (activated voltage sensor and open pore). This model can be described by three thermodynamic parameters: K~1~ is the intrinsic activation constant of the voltage sensor, K~2~ is the intrinsic activation constant of the pore, and θ represents the interaction between the activated voltage sensor and open pore. For the purposes of this analysis, we ignore the cross interaction terms as well as the interaction between the resting voltage sensor and closed pore.

![](JGP_201010438_Scheme1)

To consider the effects of local anesthetic on voltage sensor activation, we extend our initial scheme to include two new lidocaine-bound states: V~A~P~O~^L^ and V~R~P~O~^L^. We assume that the lidocaine binds to the open pore (i.e., in channel states V~R~P~O~ and V~A~P~O~), as suggested by studies on inactivation-deficient sodium channels ([@bib42]) and quaternary ammonium ([@bib1]). Studies in inactivation-deficient channels show that lidocaine-binding affinity is similar to the WT channels. For simplicity, we ignore the presence of inactivated states and lidocaine binding to the inactivated states. The addition of lidocaine modifies the above system, which is now described by [Scheme 1b](#sc1b){ref-type="disp-formula"}, where K~A~ is the association constant of lidocaine with the open pore.

![](JGP_201010438_Scheme2)

Studies on voltage-gated potassium channels suggest that the equilibrium constant for spontaneous opening of the pore is very low and, therefore, the state V~R~P~O~ is sparsely populated ([@bib14]). Therefore, [Schemes 1a](#sc1a){ref-type="disp-formula"} and [1b](#sc1b){ref-type="disp-formula"} can be rewritten as a sequential model depicted in [Schemes 2a](#sc2a){ref-type="disp-formula"} and [2b](#sc2b){ref-type="disp-formula"}.

![](JGP_201010438_Scheme3)

![](JGP_201010438_Scheme4)

The probabilities of activation of the voltage sensor, as derived from Scheme 2, with and without lidocaine are:$$P_{\mathit{VA}}\left( \mathit{unbound} \right) = \frac{K_{V} + K_{V}K_{P}}{1 + K_{V} + K_{V}K_{P}}$$$$P_{\mathit{VA}}\left( \mathit{bound} \right) = \frac{K_{V} + K_{V}K_{P} + K_{V}K_{P}K_{A}}{1 + K_{V} + K_{V}K_{P} + K_{V}K_{P}K_{A} + K_{V}K_{P}K_{A}K_{R}}$$

To determine the values of thermodynamic parameters described in Scheme 2, the equations for the probability of activation of the voltage sensor ([Eqs. 1](#fd1){ref-type="disp-formula"} and [2](#fd2){ref-type="disp-formula"}) were fitted to the WT F-V curve before and after the addition of lidocaine. The parameters that provide a reasonable fit to the WT data under both conditions are shown in [Table II](#tbl2){ref-type="table"}, and the simulated F-V curve of the WT is shown in [Fig. 6 A](#fig6){ref-type="fig"}.

###### 

Parameters obtained from fitting Scheme 2 to the F-V data

  Construct   *K~V~*^0^    Z~V~         *K~P~*^0^    Z~P~         K~A~          K~R~
  ----------- ------------ ------------ ------------ ------------ ------------- ---------------
  WT          15.2 (4.3)   1.5 (3.7)    5.8 (1.7)    0.36 (4.5)   953.3 (0.9)   0.00046 (6.9)
  A1145W      32.9 (1.8)   1.18 (2.5)   0.13 (5.6)   0.22 (5.9)   968.7 (1.4)   0.018 (5.8)
              *K*~1~^0^    Z~1~         *K*~2~^0^    Z~2~         K~A~          θ
  WT          15.2         1.5          0.041        0.36         953.3         143
  A1145W      32.9         1.18         0.076        0.22         968.7         1.7

The values of the parameters of Scheme 2, reported here, are the mean of the parameter values obtained from the 1,000 fitting procedures (refer to Materials and methods). The standard deviation, expressed as a percentage of the mean, of each parameter is reported in parentheses. From the fitted values of K~V~, K~P~, and K~R~, the intrinsic parameters *K*~1~^0^, *K*~2~^0^, and θ were derived using the relations provided in Eq. 3.

![Simulations of fluorescence activation curves of WT and a mutant before and after the addition of lidocaine. The equations describing the probability of activation of the voltage sensor were fitted to the WT data (A) and A1145W (B) to generate the activation curves shown above (refer to Materials and methods). Symbols represent the simulated data points, and the trend lines are fits of the simulated data with a single Boltzmann function.](JGP_201010438R_LW_Fig6){#fig6}

Why does lidocaine binding cause a shift in the F-V curve? A comparison of [Schemes 2a](#sc2a){ref-type="disp-formula"} and [2b](#sc2b){ref-type="disp-formula"} reveals that in the absence of lidocaine, the F-V curves reflect the transition between V~R~P~C~ to V~A~P~C~. Saturating concentrations of lidocaine drive the equilibrium rightwards, and the system transits primarily between two possible states: V~R~P~O~^L^ and V~A~P~O~^L^. Under these conditions, the F-V curves primarily track the transition between the states V~R~P~O~^L^ and V~A~P~O~^L^. To understand the thermodynamic implication of this shift, we can see that the general model (Scheme 1) can be reduced to the sequential model when V~R~P~O~ has negligible contribution (see [supplemental text](http://www.jgp.org/cgi/content/full/jgp.201010438/DC1)). Thus, the thermodynamic parameters in Scheme 2 are related to Scheme 1 as:$$K_{V} = K_{1}$$$$K_{P} = \theta\, K_{2}$$$$K_{A} = K_{A}$$$$K_{R} = 1/\theta\, K_{1}$$

Examination of the above relationships shows that the equilibrium constant for V~R~P~C~ to V~A~P~C~ transition is *K*~1~, whereas that for the V~R~P~O~^L^ to V~A~P~O~^L^ transition is θ*K*~1~. Because the voltage sensor and pore are positively coupled to each other (θ greater than 1), the activation of the voltage sensor is always favored in the presence of lidocaine. This analysis also shows that when θ tends to 1, the transitions V~R~P~C~ to V~A~P~C~ and V~R~P~O~^L^ to V~A~P~O~^L^ will become energetically identical. Under these conditions, the binding of lidocaine to the pore is going to have small or no effects on the movement of the voltage sensor.

The equations governing the probability of activation of the voltage sensor in the absence and presence of lidocaine ([Eqs. 1](#fd1){ref-type="disp-formula"} and [2](#fd2){ref-type="disp-formula"}) were fitted to the F-V traces of one of the high impact mutants, A1145W ([Fig. 6 B](#fig6){ref-type="fig"}). Examination of the fitted parameters for the mutant ([Table II](#tbl2){ref-type="table"}) shows that this mutation mostly affects the K~R~ and K~P~ terms. Expressing the K~R~ and K~P~ in terms of K~1~, K~2~, and θ (using Eq. 3) reveals that this interaction term is reduced by 80-fold in the A1145W mutant. This large change in coupling term accounts for most of the reduction in the lidocaine-induced shifts of F-V curves in mutant channels. We note that although the Monte Carlo--like-fitting algorithm efficiently samples a larger parameter space (varying over four orders of magnitude), we cannot eliminate the possibility that the equilibrium values reported in [Table II](#tbl2){ref-type="table"} are just one set of values that describe our data. Therefore, we cannot completely rule out other mechanisms to explain the lidocaine-induced fluorescence changes.

By examining the effect of these mutations on the probabilities of voltage sensor and pore opening in the absence of lidocaine, we can also make inferences regarding the thermodynamic effects of these mutations. The above analysis shows that the mutations where the interaction between activated voltage sensor and open pore is disrupted would exhibit small shifts in the F-V upon the addition of lidocaine. This would also cause rightward shifts in the F-V and G-V curves of this mutant in the absence of lidocaine, which was observed for the V1142W mutant ([@bib22]). A similar loss of coupling interactions between the resting-state voltage sensor and closed pore can account for small shifts in F-V curves upon lidocaine application (supplemental text). Three of the high impact mutants at I1284, I1287, and K1295 cause a leftward shift in the activation probability curves of the voltage sensor and pore opening, which suggests that these mutations disrupt the resting-state interactions between the voltage sensor and pore. The remaining two mutants, R1135W and A1145W, both cause opposite effects on the activation probabilities of the voltage sensor and pore. In these mutants, the closed state of the pore is stabilized while the voltage sensor is stabilized in the activated state. The effects of these mutants are consistent with the idea that these mutations disrupt resting-state and activated-state interactions ([@bib22]).

In sum, our analysis suggests that the mutations that disrupt coupling interactions between the voltage sensor and pore would reduce the lidocaine-induced shift in F-V curves. All sites identified by [@bib22] except the S1134W cause reduced shifts in the F-V curves upon the addition of lidocaine. Moreover, only the residues that contribute both to the resting-state and activated-state interactions were identified in that study. By examining the effect of lidocaine on the mutations at the domain III intracellular gating interface, we are able to identify a larger set of residues that are important for voltage sensor and pore coupling. More specifically, this study also identifies the residues that mainly contribute to resting-state interactions and those that are involved in the activated-state interactions. Nonetheless, this interpretation should be considered tentative because it is based on the premise that lidocaine binding does not produce a channel pore with a very different structure, but primarily alters the energetics associated with pore opening and closing transition.

Mapping the mutations on a structural model of the sodium channel
-----------------------------------------------------------------

The positions of the decoupling mutants were mapped onto a surface representation of a homology model of Nav1.4 ([Fig. 7, A and B](#fig7){ref-type="fig"}) and the isolated domain III ([Fig. 7, C and D](#fig7){ref-type="fig"}). The residues were color-coded based on the degree of shift in the domain III voltage sensor activation upon drug application. These mutants were mostly localized in the S4--S5 linker region and the lower end of the S6 segment. In the S4--S5 linker, they were exclusively limited to one face of the helix, indicating that this face plays a key role in coupling drug binding to voltage sensor activation. In contrast, such a clear pattern was not obvious in the S6 helix. Almost every residue in the stretch between L1282 to K1295 reduces the shifts in the domain III voltage sensor to a varying extent. One possibility is that the S6 helix, being in a tightly packed region near the bundle crossing, is likely to interact promiscuously with the neighboring S6 segments in addition to its own S5 helix and S4--S5 linker. The introduction of tryptophan into this region causes a leftward shift in the F-V and G-V curves ([@bib22]) in almost all the positions, consistent with the interpretation that these residues disrupt interactions between the voltage sensor and the pore in the resting state. Scanning mutagenesis studies in potassium channels show that most mutations in the S6 region near the bundle crossing stabilize the open pore, presumably by disrupting the packing in the closed state ([@bib48]; [@bib44]).

![Mapping the mutations that perturb allosteric modification by lidocaine. (A) Surface representation of the Nav1.4 sodium channel model with mutations that disrupt the communication between the lidocaine-binding site and voltage sensor, viewed from the intracellular side. A color gradient from yellow to red was used to represent ΔV~1/2~ changes induced upon the addition of lidocaine. (B) Same as in A after the structure was rotated by 90°. The domains I and IV are hidden from view by the other two domains. (C) Surface representation of domain III of the Nav1.4 channel. The other three domains were removed for clarity. The residues were color-coded as in A. (D) A close-up view of the S4--S5 linker, N terminus of S5, and C terminus of S6, with transparent surfaces and side chains colored as in A. All of these structures were drawn using PyMol (DeLano Scientific LLC).](JGP_201010438_RGB_Fig7){#fig7}

Preliminary model of allosteric modulation
------------------------------------------

Finally, we consider a working model to rationalize the modification of voltage-dependent gating by intracellular pore blockers ([Fig. 8](#fig8){ref-type="fig"}). The main assumption is that lidocaine-like quaternary ammonium compounds upon binding to the sodium channel prevent the pore from fully closing ([@bib1]). Furthermore, we have shown recently that lidocaine has the largest effect on the S6 segment of domain III ([@bib21]). This imposes an energetic cost on the return of the domain III S6 segment to a closed position when the membrane is repolarized. This destabilization of the closed pore by lidocaine binding would propagate to the domain III voltage sensor because they are coupled. Therefore, lidocaine binding would shift the voltage-dependent activation of the domain III voltage sensor to more hyperpolarized potentials. Our finding that a strong hyperpolarization can drive the voltage sensor to a resting-state conformation suggests that either the pore gates are able to close even when the lidocaine is bound to the channel, or that an intermediate state corresponding to a resting domain III voltage sensor and S6 domain III in an open conformation is populated. At present, we are unable to clearly distinguish between these two possibilities because of a lack of a conformational probe for tracking the dynamics of individual pore segments. Despite these limitations, our study provides strong evidence that the intracellular gating interface is a major pathway for allosteric coupling between the drug-binding site and the voltage-sensing domains.

![Plausible model for voltage sensor modification by local anesthetics. Upon depolarization, the voltage sensors move outward and the pore of the sodium channel opens. For clarity, only domains I and III are shown. Lidocaine binds to the open pore with high affinity (open lidocaine bound). When the membrane is repolarized, the domain III pore helices are unable to close because of lidocaine occupying the binding site and destabilizing the resting state of the domain III voltage sensor relative to the open state. Strong hyperpolarization drives the domain III voltage sensor to a resting-like conformation, even though the lidocaine-binding site is occupied.](JGP_201010438_RGB_Fig8){#fig8}
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